The NASA Mars Sample Return program is encountering resistance from the planetary science community due to proposed budget language that would terminate the current mission framework. In early January ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

View post: Winter Storm Warning: 2 Feet of Snow & 90 MPH Gusts Barrel Toward I-80 at Donner Pass, Lake Tahoe, and Yosemite Porsche faces a myriad of problems in China. For one, the brand’s cars are ...

Here is a sampling of some of the electives taken by MAM students offered by the Yale School of the Environment. Here is a sampling of some of the electives taken by MAM students offered by the ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio ...

Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...

You’ve probably heard of Porsche’s Paint to Sample program that allows customers to spec their car in colors not listed among the stock color swatches. But did you know it’s not just one program, but ...

(RTTNews) - Recursion Pharmaceuticals, Inc. (RXRX), a clinical-stage TechBio company, on Monday, announced that it is deprioritizing three of its clinical programs and one preclinical program ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...